Study Suggests Elvitegravir Produces Rapid Virologic Suppression in Treatment-Experienced People on Active Background Therapy

Written by AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) on March 5, 2010 – 12:00 am -

“This phase 2, randomized, active-controlled, 48-week study assessed the noninferiority of the human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease inhibitor (CPI/r) in treatment-experienced subjects. … Subjects had HIV RNA levels 1000 copies/mL and 1 protease resistance mutation. Subjects received nucleoside or nucleotide reverse-transcriptase inhibitors (NRTIs) with or without T-20 and either CPI/r or once-daily elvitegravir at a dose of 20 mg, 50 mg, or 125 mg (blinded to dose) with ritonavir. After week 8, the independent data monitoring committee stopped the elvitegravir 20 mg arm and allowed subjects in the elvitegravir 50 mg and 125 mg arms to add protease inhibitors. The primary end point was the time-weighted average change from baseline in HIV RNA level through week 24 (DAVG(24)). … A total of 278 subjects with a median of 11 protease and 3 thymidine analog mutations were randomized and treated. One-half of subjects received NRTIs without expected antiviral activity. Compared with the DAVG(24) for the CPI/r arm (-1.19 log(10) copies/mL), the elvitegravir 50 mg arm was noninferior (-1.44 log(10) copies/mL), and the elvitegravir 125 mg arm was superior (-1.66 log(10) copies/mL; …). Efficacy was impacted by activity of background agents. There was no relationship between elvitegravir dosage and adverse events. … Elvitegravir was well-tolerated and produced rapid virologic suppression that was durable with active background therapy.”

More information is available:


Posted in AIDS | Comments Off

Study Suggests Overall Treatment Outcomes Similar in Once-Daily versus Twice-Daily Combination Antiretroviral Therapy Despite Adherence Differences

March 5, 2010 – 12:00 am

“Dosing frequency is an important determinant of regimen effectiveness. ...To ...

Comments Off

Join AIDSinfo in Observing National Women and Girls HIV/AIDS Awareness Day

March 5, 2010 – 12:00 am

March 10 is National Women and Girls HIV/AIDS Awareness Day ...

Comments Off

Reported at CROI: Early Development of Gene Therapy for HIV Promising

March 5, 2010 – 12:00 am

“Existing AIDS drugs allow many patients to live fairly normal ...

Comments Off

FDA Reports: Clinical Trial Data Suggest the Combination of Invirase (Saquinavir) and Norvir (Ritonavir) May Affect the Electrical Activity of the Heart

March 5, 2010 – 12:00 am

“The U.S. Food and Drug Administration (FDA) is reviewing clinical ...

Comments Off

Study Suggests Brief, Intense Raltegravir Treatment Does Not Reduce Persistent Viremia in People on a Suppressive HAART Regimen

March 5, 2010 – 12:00 am

“We investigated whether intensification with the integrase inhibitor raltegravir decreases ...

Comments Off

Study Suggests Aciclovir May Slow HIV-1 Disease Progression in People Coinfected with HIV-1 and HSV-2

March 5, 2010 – 12:00 am

“Most people infected with HIV-1 are dually infected with herpes ...

Comments Off

Study Suggests Inactivated Mycobacterial Vaccine May Prevent Tuberculosis in Bacille Calmette-Guérin-Primed, HIV-Infected Adults

March 5, 2010 – 12:00 am

“The DarDar trial was a randomized, placebo-controlled, double-blind trial. The ...

Comments Off

Study Indicates that Racial and Ethnic Minorities Experience Higher Perinatal HIV Infection Rates

March 5, 2010 – 12:00 am

“Despite substantial declines in the number of HIV-infected infants in ...

Comments Off

Norvir (Ritonavir) Product Label Updated with Newly Approved Tablet Information

March 5, 2010 – 12:00 am

“On February 10, 2010, FDA approved Norvir (ritonavir) 100 mg ...

Comments Off